Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude

Sergio Caravita, Andrea Faini, Carolina Lombardi, Mariaconsuelo Valentini, Francesca Gregorini, Jessica Rossi, Paolo Meriggi, Marco Di Rienzo, Grzegorz Bilo, Piergiuseppe Agostoni, Gianfranco Parati

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sexrelated difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. Methods: Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level offtreatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. Results: Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. Conclusions: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. Trial Registry: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu

Original languageEnglish
Pages (from-to)120-131
Number of pages12
JournalChest
Volume147
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Acetazolamide
Sleep
Respiration
Oceans and Seas
Placebos
Apnea
Registries
Clinical Trials

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude. / Caravita, Sergio; Faini, Andrea; Lombardi, Carolina; Valentini, Mariaconsuelo; Gregorini, Francesca; Rossi, Jessica; Meriggi, Paolo; Di Rienzo, Marco; Bilo, Grzegorz; Agostoni, Piergiuseppe; Parati, Gianfranco.

In: Chest, Vol. 147, No. 1, 01.01.2015, p. 120-131.

Research output: Contribution to journalArticle

@article{a8a157762f7e432a985f0f9d7a935858,
title = "Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude",
abstract = "Objective: Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sexrelated difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. Methods: Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level offtreatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. Results: Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. Conclusions: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. Trial Registry: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu",
author = "Sergio Caravita and Andrea Faini and Carolina Lombardi and Mariaconsuelo Valentini and Francesca Gregorini and Jessica Rossi and Paolo Meriggi and {Di Rienzo}, Marco and Grzegorz Bilo and Piergiuseppe Agostoni and Gianfranco Parati",
year = "2015",
month = "1",
day = "1",
doi = "10.1378/chest.14-0317",
language = "English",
volume = "147",
pages = "120--131",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Sex and acetazolamide effects on chemoreflex and periodic breathing during sleep at altitude

AU - Caravita, Sergio

AU - Faini, Andrea

AU - Lombardi, Carolina

AU - Valentini, Mariaconsuelo

AU - Gregorini, Francesca

AU - Rossi, Jessica

AU - Meriggi, Paolo

AU - Di Rienzo, Marco

AU - Bilo, Grzegorz

AU - Agostoni, Piergiuseppe

AU - Parati, Gianfranco

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sexrelated difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. Methods: Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level offtreatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. Results: Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. Conclusions: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. Trial Registry: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu

AB - Objective: Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sexrelated difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. Methods: Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level offtreatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. Results: Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. Conclusions: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. Trial Registry: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu

UR - http://www.scopus.com/inward/record.url?scp=84920722556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920722556&partnerID=8YFLogxK

U2 - 10.1378/chest.14-0317

DO - 10.1378/chest.14-0317

M3 - Article

C2 - 25188815

AN - SCOPUS:84920722556

VL - 147

SP - 120

EP - 131

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -